Screener
Iovance Biotherapeutics, Inc. IOVA Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesAndOtherLiabilities.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current Liabilities | ||
| Accounts payable | $26,211 | $22,159 |
| Accrued expenses and other liabilities | 77,964 | 111,156 |
| Note payable - current | — | 1,000 |
| Operating lease liabilities | 2,673 | 4,043 |
| Total Current Liabilities | 106,848 | 138,358 |
| Non-Current Liabilities |
Item 1.Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Iovance Biotherapeutics, Inc.'s accrued expenses?
- Iovance Biotherapeutics, Inc. (IOVA) reported accrued expenses of $77.96M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s accrued expenses changed year-over-year?
- Iovance Biotherapeutics, Inc.'s accrued expenses decreased by 12.5% year-over-year, from $89.08M to $77.96M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s accrued expenses?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s accrued expenses has grown at a 25.9% compound annual growth rate (CAGR), from $35.07M to $111.16M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Iovance Biotherapeutics, Inc.'s accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude